Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation

Eiichi Watanabe, Yoshihiro Sobue, Kan Sano, Kentarou Okuda, Mayumi Yamamoto, Yukio Ozaki

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: n-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA), has been reported to have antiarrhythmic and antiinflammatory effects. The aim of the present study was to examine whether the combination of antiarrhythmic drugs and EPA reduced the frequency of atrial fibrillation (AF) in patients with paroxysmal AF. Methods: We studied 50 patients with paroxysmal AF (age, 54 ± 9 years) after excluding the clinical conditions associated with an increased risk of AF. Patients were initially treated with antiarrhythmic drugs for 6 months (the observation period), and thereafter, EPA was added at a dose of 1.8 g/day for 6 months (the intervention period). During a one-year period, patients obtained an ECG recording using a portable device each morning and when arrhythmia-related symptom occurred. The end point was the difference of the AF burden (defined by the days of AF per month) between observation period and intervention period. Plasma EPA and C-reactive protein (CRP) levels were also determined. Results: There was no significant difference in the AF burden before and after intervention (2.6 ± 2.2 days/months vs. 2.5 ± 2.2 days/months, P = 0.45). Although EPA level was significantly increased (42 ± 15 μ/mL to 120 ± 47 μ/mL, P < 0.001), CRP level was unchanged (1.04 ± 0.69 mg/L to 0.96 ± 0.56 mg/L, P = 0.24) following EPA treatment. Conclusions: Treatment of EPA in combination with antiarrhythmic drugs did not reduce the AF burden or the CRP levels in paroxysmal AF patients who had no evidence of substantial structural heart disease.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalAnnals of Noninvasive Electrocardiology
Volume16
Issue number4
DOIs
Publication statusPublished - 01-10-2011

Fingerprint

Eicosapentaenoic Acid
Atrial Fibrillation
Anti-Arrhythmia Agents
C-Reactive Protein
Observation
Omega-3 Fatty Acids
Cardiac Arrhythmias
Heart Diseases
Electrocardiography
Anti-Inflammatory Agents
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Watanabe, Eiichi ; Sobue, Yoshihiro ; Sano, Kan ; Okuda, Kentarou ; Yamamoto, Mayumi ; Ozaki, Yukio. / Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. In: Annals of Noninvasive Electrocardiology. 2011 ; Vol. 16, No. 4. pp. 373-378.
@article{f67be1fcfde64e6c82299c3043b40fbd,
title = "Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation",
abstract = "Background: n-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA), has been reported to have antiarrhythmic and antiinflammatory effects. The aim of the present study was to examine whether the combination of antiarrhythmic drugs and EPA reduced the frequency of atrial fibrillation (AF) in patients with paroxysmal AF. Methods: We studied 50 patients with paroxysmal AF (age, 54 ± 9 years) after excluding the clinical conditions associated with an increased risk of AF. Patients were initially treated with antiarrhythmic drugs for 6 months (the observation period), and thereafter, EPA was added at a dose of 1.8 g/day for 6 months (the intervention period). During a one-year period, patients obtained an ECG recording using a portable device each morning and when arrhythmia-related symptom occurred. The end point was the difference of the AF burden (defined by the days of AF per month) between observation period and intervention period. Plasma EPA and C-reactive protein (CRP) levels were also determined. Results: There was no significant difference in the AF burden before and after intervention (2.6 ± 2.2 days/months vs. 2.5 ± 2.2 days/months, P = 0.45). Although EPA level was significantly increased (42 ± 15 μ/mL to 120 ± 47 μ/mL, P < 0.001), CRP level was unchanged (1.04 ± 0.69 mg/L to 0.96 ± 0.56 mg/L, P = 0.24) following EPA treatment. Conclusions: Treatment of EPA in combination with antiarrhythmic drugs did not reduce the AF burden or the CRP levels in paroxysmal AF patients who had no evidence of substantial structural heart disease.",
author = "Eiichi Watanabe and Yoshihiro Sobue and Kan Sano and Kentarou Okuda and Mayumi Yamamoto and Yukio Ozaki",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1542-474X.2011.00465.x",
language = "English",
volume = "16",
pages = "373--378",
journal = "Annals of Noninvasive Electrocardiology",
issn = "1082-720X",
publisher = "Wiley-Blackwell",
number = "4",

}

Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation. / Watanabe, Eiichi; Sobue, Yoshihiro; Sano, Kan; Okuda, Kentarou; Yamamoto, Mayumi; Ozaki, Yukio.

In: Annals of Noninvasive Electrocardiology, Vol. 16, No. 4, 01.10.2011, p. 373-378.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eicosapentaenoic acid for the prevention of recurrent atrial fibrillation

AU - Watanabe, Eiichi

AU - Sobue, Yoshihiro

AU - Sano, Kan

AU - Okuda, Kentarou

AU - Yamamoto, Mayumi

AU - Ozaki, Yukio

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background: n-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA), has been reported to have antiarrhythmic and antiinflammatory effects. The aim of the present study was to examine whether the combination of antiarrhythmic drugs and EPA reduced the frequency of atrial fibrillation (AF) in patients with paroxysmal AF. Methods: We studied 50 patients with paroxysmal AF (age, 54 ± 9 years) after excluding the clinical conditions associated with an increased risk of AF. Patients were initially treated with antiarrhythmic drugs for 6 months (the observation period), and thereafter, EPA was added at a dose of 1.8 g/day for 6 months (the intervention period). During a one-year period, patients obtained an ECG recording using a portable device each morning and when arrhythmia-related symptom occurred. The end point was the difference of the AF burden (defined by the days of AF per month) between observation period and intervention period. Plasma EPA and C-reactive protein (CRP) levels were also determined. Results: There was no significant difference in the AF burden before and after intervention (2.6 ± 2.2 days/months vs. 2.5 ± 2.2 days/months, P = 0.45). Although EPA level was significantly increased (42 ± 15 μ/mL to 120 ± 47 μ/mL, P < 0.001), CRP level was unchanged (1.04 ± 0.69 mg/L to 0.96 ± 0.56 mg/L, P = 0.24) following EPA treatment. Conclusions: Treatment of EPA in combination with antiarrhythmic drugs did not reduce the AF burden or the CRP levels in paroxysmal AF patients who had no evidence of substantial structural heart disease.

AB - Background: n-3 polyunsaturated fatty acids, primarily eicosapentaenoic acid (EPA), has been reported to have antiarrhythmic and antiinflammatory effects. The aim of the present study was to examine whether the combination of antiarrhythmic drugs and EPA reduced the frequency of atrial fibrillation (AF) in patients with paroxysmal AF. Methods: We studied 50 patients with paroxysmal AF (age, 54 ± 9 years) after excluding the clinical conditions associated with an increased risk of AF. Patients were initially treated with antiarrhythmic drugs for 6 months (the observation period), and thereafter, EPA was added at a dose of 1.8 g/day for 6 months (the intervention period). During a one-year period, patients obtained an ECG recording using a portable device each morning and when arrhythmia-related symptom occurred. The end point was the difference of the AF burden (defined by the days of AF per month) between observation period and intervention period. Plasma EPA and C-reactive protein (CRP) levels were also determined. Results: There was no significant difference in the AF burden before and after intervention (2.6 ± 2.2 days/months vs. 2.5 ± 2.2 days/months, P = 0.45). Although EPA level was significantly increased (42 ± 15 μ/mL to 120 ± 47 μ/mL, P < 0.001), CRP level was unchanged (1.04 ± 0.69 mg/L to 0.96 ± 0.56 mg/L, P = 0.24) following EPA treatment. Conclusions: Treatment of EPA in combination with antiarrhythmic drugs did not reduce the AF burden or the CRP levels in paroxysmal AF patients who had no evidence of substantial structural heart disease.

UR - http://www.scopus.com/inward/record.url?scp=80054814575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054814575&partnerID=8YFLogxK

U2 - 10.1111/j.1542-474X.2011.00465.x

DO - 10.1111/j.1542-474X.2011.00465.x

M3 - Article

C2 - 22008493

AN - SCOPUS:80054814575

VL - 16

SP - 373

EP - 378

JO - Annals of Noninvasive Electrocardiology

JF - Annals of Noninvasive Electrocardiology

SN - 1082-720X

IS - 4

ER -